

ASX Listing Rule 3.16.4 Disclosure

Visionflex Group Limited (“**VFX**” or the “**Company**”) refers to the Board restructure announced on 21 February 2025 which took effect on 1 March 2025.

In accordance with ASX listing rule 3.16.4, VFX advises that to better align with shareholder interests and support the Company’s long-term objectives, the new Board members, Joshua Munday (Managing Director and Chief Executive Officer), Michael Kafrouni (Executive Director and Chief Operating Officer) and previous Board member and new Chairman (Brook Adcock), have voluntarily decided to forgo any Director fees for the current financial year.

This decision reflects the Board’s commitment to maximising shareholder value. Mr Munday and Mr Kafrouni’s existing employment agreements remain unchanged, and details of the Executive Directors’ remuneration can be found on page 27 of the 2024 Annual Report (Remuneration of KMP table).

-- END --

This announcement was approved for release by the Board of Directors.

For more information:

Joshua Munday
Managing Director and CEO, Visionflex Group
jmunday@visionflex.com

About Visionflex Group

At Visionflex, we believe that healthcare should be accessible, efficient, and connected. Our integrated hardware and software platform allows healthcare providers to deliver comprehensive, collaborative care in real time, no matter the location. From metropolitan health networks to community-based care, Visionflex is reshaping how healthcare is delivered by connecting healthcare teams with the tools and technology needed to provide effective, efficient, and high-quality care.

For more information, visit vfx-group.com